Urinary 20-hydroxyeicosatetraenoic Acid is Associated with Endothelial Dysfunction in Humans
Overview
Authors
Affiliations
Background: 20-hydroxyeicosatetraenoic acid (20-HETE) is a cytochrome P450 (omega-hydroxylase) metabolite of arachidonic acid with vasoconstrictor activity that may be involved in the pathogenesis of hypertension. In humans, there are few data relating 20-HETE to vascular pathophysiology. This study aimed to determine whether urinary 20-HETE excretion is related to blood pressure or vascular endothelial function in humans.
Methods And Results: Sixty-six subjects (37 males, 29 females), including 29 with untreated hypertension, had urinary 20-HETE excretion measured by gas chromatography/mass spectrometry. There was no significant difference for 20-HETE excretion between hypertensive and normotensive subjects. 20-HETE excretion was positively related to body mass index and sodium excretion. There was a significant inverse association between urinary 20-HETE and endothelium-dependent vasodilation measured by flow-mediated dilation of the brachial artery (P=0.006). There was no association with vasodilator responses to nitroglycerin. In multiple regression analysis, 20-HETE remained an independent predictor of endothelium-dependent vasodilation after adjustment for age, body mass index, and blood pressure. When gender was included in the model, the relationship between 20-HETE and flow-mediated dilation was attenuated. Separate analysis by gender revealed that in women, hypertensive subjects had significantly higher 20-HETE excretion than normotensive subjects, but this was not seen in men. In women, 20-HETE was positively related to diastolic and systolic blood pressure. In men, 20-HETE was positively related to body mass index.
Conclusions: This is the first demonstration of an association between 20-HETE excretion and in vivo vascular function in humans. Given the negative modulatory role of nitric oxide on omega-hydroxylase, the present results suggest a potentially important role for 20-HETE in human vascular physiology.
Dia B, Alkhansa S, Njeim R, Al Moussawi S, Farhat T, Haddad A Pharmaceutics. 2023; 15(3).
PMID: 36986825 PMC: 10054805. DOI: 10.3390/pharmaceutics15030965.
Clinical significance of polyunsaturated fatty acids in the prevention of cardiovascular diseases.
Kotlyarov S, Kotlyarova A Front Nutr. 2022; 9:998291.
PMID: 36276836 PMC: 9582942. DOI: 10.3389/fnut.2022.998291.
Baranowska I, Gawrys O, Walkowska A, Olszynski K, Cervenka L, Falck J Front Pharmacol. 2022; 12:798642.
PMID: 35111064 PMC: 8802114. DOI: 10.3389/fphar.2021.798642.
Duflot T, Moreau-Grange L, Roche C, Iacob M, Wils J, Remy-Jouet I Cardiovasc Diabetol. 2019; 18(1):35.
PMID: 30885203 PMC: 6423843. DOI: 10.1186/s12933-019-0843-z.
Is renal tubular cadmium toxicity clinically relevant?.
Boonprasert K, Vesey D, Gobe G, Ruenweerayut R, Johnson D, Na-Bangchang K Clin Kidney J. 2018; 11(5):681-687.
PMID: 30288264 PMC: 6165745. DOI: 10.1093/ckj/sfx153.